This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1vdv

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1vdv.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1vdv.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1vdv| PDB=1vdv | SCENE= }}
{{STRUCTURE_1vdv| PDB=1vdv | SCENE= }}
-
'''Bovine Milk Xanthine Dehydrogenase Y-700 Bound Form'''
+
===Bovine Milk Xanthine Dehydrogenase Y-700 Bound Form===
-
==Overview==
+
<!--
-
Y-700 (1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid) is a newly synthesized inhibitor of xanthine oxidoreductase (XOR). Steady-state kinetics with the bovine milk enzyme indicated a mixed type inhibition with K(i) and K(i) ' values of 0.6 and 3.2 nM, respectively. Titration experiments showed that Y-700 bound tightly both to the active sulfo-form and to the inactive desulfo-form of the enzyme with K(d) values of 0.9 and 2.8 nM, respectively. X-ray crystallographic analysis of the enzyme-inhibitor complex revealed that Y-700 closely interacts with the channel leading to the molybdenum-pterin active site but does not directly coordinate to the molybdenum ion. In oxonate-treated rats, orally administered Y-700 (1-10 mg/kg) dose dependently lowered plasma urate levels. At a dose of 10 mg/kg, the hypouricemic action of Y-700 was more potent and of longer duration than that of 4-hydroxypyrazolo(3,4-d)pyrimidine, whereas its action was approximately equivalent to that of 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid, a nonpurine inhibitor of XOR. In normal rats, orally administered Y-700 (0.3-3 mg/kg) dose dependently reduced the urinary excretion of urate and allantoin, accompanied by an increase in the excretion of hypoxanthine and xanthine. Y-700 (1 mg/kg) was absorbed rapidly by the oral route with high bioavailability (84.1%). Y-700 was hardly excreted via the kidneys but was mainly cleared via the liver. These results suggest that Y-700 will be a promising candidate for the treatment of hyperuricemia and other diseases in which XOR may be involved.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15190124}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15190124 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15190124}}
==About this Structure==
==About this Structure==
Line 34: Line 38:
[[Category: Xanthine oxidoreductase]]
[[Category: Xanthine oxidoreductase]]
[[Category: Y-700]]
[[Category: Y-700]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 12:25:19 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 14:56:10 2008''

Revision as of 11:56, 28 July 2008

Image:1vdv.png

Template:STRUCTURE 1vdv

Bovine Milk Xanthine Dehydrogenase Y-700 Bound Form

Template:ABSTRACT PUBMED 15190124

About this Structure

1VDV is a Single protein structure of sequence from Bos taurus. Full crystallographic information is available from OCA.

Reference

Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion., Fukunari A, Okamoto K, Nishino T, Eger BT, Pai EF, Kamezawa M, Yamada I, Kato N, J Pharmacol Exp Ther. 2004 Nov;311(2):519-28. Epub 2004 Jun 9. PMID:15190124

Page seeded by OCA on Mon Jul 28 14:56:10 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1vdv"
Personal tools